Targeting natural killer cells to enhance HIV vaccine responses

针对自然杀伤细胞增强艾滋病毒疫苗反应

基本信息

  • 批准号:
    10471839
  • 负责人:
  • 金额:
    $ 65.57万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-08-01 至 2024-07-31
  • 项目状态:
    已结题

项目摘要

PI: Waggoner, Stephen Noel, “Targeting natural killer cells to enhance HIV vaccine responses” ABSTRACT Immunization represents one of the most successful public health interventions in human history, preventing more than 2 million deaths each year. Most licensed vaccines work by eliciting antibodies that can prevent infection by neutralizing the invading pathogen. However, vaccine-mediated induction of broadly neutralizing antibodies capable of thwarting infection with a highly mutable pathogen like HIV has proven exceptionally difficult in both humans and animal models. This shortcoming in vaccine success is likely due to intrinsic immune regulatory mechanisms that limit the quantity and quality of immune responses. Development of translational means to overcome these immunological roadblocks holds great promise for advancement of next-generation vaccines to prevent infection and improve global health. Our research focuses on the remarkable capacity of natural killer (NK) cells to suppress T and B cell responses. NK cells limit the magnitude and quality of adaptive immune memory triggered after immunization. This activity of NK cells impairs the generation of protective neutralizing antibody responses by restricting somatic mutation and affinity maturation of these antibodies within germinal centers. We find that a subset of transcriptionally unique NK cells migrates to sites of germinal center formation following immunization and contributes to suppression of follicular helper T cells (Tfh) differentiation via perforin-mediated elimination of activated CD4 T cells. We identify key effector molecules, receptors, and transcription factors that are putatively vital for this immunosuppressive activity of NK cells, and therefore represent innovative targets to enhance vaccine efficacy. The overall objective of this proposal is to test the scientific premise that cytotoxic functions of NK cells limit vaccine-mediated generation of HIV-specific broadly neutralizing antibodies. We propose three thematically connected aims that explore the contributions of various mediators that determine the cytotoxic immunoregulatory capacity of NK cells during immunization. In Aim 1, we will use cutting-edge knock-in mice to test the hypothesis that transient small molecule inhibition of NK-cell cytolytic function during immunization can safely and effective augment germinal center-mediated maturation of HIV-specific antibody responses. In Aim 2, we will use innovative bone marrow chimera and conditional knock-out mice to define the role of a network of transcription factors, chemokine receptors, and integrins in localization of NK cells near developing Tfh to facilitate cytolysis of these target cells. In Aim 3, we will use a new strain of mice and pioneering CRISPR-based screens to discover receptors involved in promotion or restraint of NK-cell killing of CD4 T cells. These experiments will define factors that enable and calibrate NK-cell suppression of adaptive immune responses during infection. Thus, the proposed work will facilitate subsequent development and deployment of innovative strategies to enhance HIV vaccine efficacy.
少年派:斯蒂芬·诺尔的瓦格纳,“以自然杀伤细胞为靶点,增强艾滋病毒疫苗的反应” 摘要 免疫接种是人类历史上最成功的公共卫生干预措施之一,预防 每年有200多万人死亡。大多数获得许可的疫苗都是通过诱导抗体来预防 通过中和入侵的病原体而感染。然而,疫苗介导的广泛中和诱导 能够阻止感染像艾滋病毒这样高度变异的病原体的抗体已经被证明是异常的 在人类和动物模型中都是困难的。疫苗成功的这一缺陷很可能是由于固有免疫。 限制免疫反应数量和质量的调节机制。翻译学的发展 克服这些免疫障碍的方法为下一代的进步带来了巨大的希望 预防感染和改善全球健康的疫苗。 我们的研究重点是自然杀伤(NK)细胞抑制T和B细胞反应的非凡能力。 NK细胞限制免疫后触发的获得性免疫记忆的大小和质量。本练习 NK细胞通过限制体细胞突变影响保护性中和抗体的产生 以及这些抗体在生发中心内的亲和力成熟。我们发现转录上的一个子集 独特的NK细胞在免疫后迁移到生发中心形成部位,并有助于 穿孔素介导的活化CD4T消除抑制滤泡辅助性T细胞分化 细胞。我们确定了关键的效应分子、受体和转录因子,这些都可能对此至关重要。 NK细胞的免疫抑制活性,因此是提高疫苗效力的创新靶点。 这项提案的总体目标是测试科学前提,即NK细胞的细胞毒功能限制 疫苗介导的艾滋病毒特异性广谱中和抗体的产生。我们分三个主题提出 相互关联的目标,探索决定细胞毒性的各种介质的作用 免疫过程中NK细胞的免疫调节能力。在目标1中,我们将使用尖端的敲入鼠标来 检验免疫期间对NK细胞杀伤功能的一过性小分子抑制可以 安全有效地增强生发中心介导的HIV特异性抗体反应的成熟。在AIM 2,我们将使用创新的骨髓嵌合体和条件性基因敲除小鼠来定义 转录因子、趋化因子受体和整合素在Tfh-TO发育期NK细胞定位中的作用 促进这些靶细胞的细胞溶解。在目标3中,我们将使用一种新的小鼠品系,并开创基于CRISPR的 筛选参与促进或抑制NK细胞对CD4T细胞杀伤的受体。这些 实验将定义能够实现和校准适应性免疫反应的NK细胞抑制的因素 在感染期间。因此,拟议的工作将有助于随后开发和部署创新的 提高艾滋病毒疫苗效力的战略。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Stephen N. Waggoner其他文献

Fas Ligand Is Responsible for CXCR3 Chemokine Induction in CD4+ T Cell-Dependent Liver Damage1
Fas 配体负责 CD4 T 细胞依赖性肝损伤中 CXCR3 趋化因子的诱导1
  • DOI:
  • 发表时间:
    2006
  • 期刊:
  • 影响因子:
    4.4
  • 作者:
    Michael W. Cruise;John R. Lukens;Aileen P. Nguyen;Matthew G. Lassen;Stephen N. Waggoner;Y. Hahn
  • 通讯作者:
    Y. Hahn
This information is current as Expression of the Chemokine CCL 8 Curbs Host Defenses by Suppressing The Transcriptional Repressor BLIMP 1
此信息最新为趋化因子 CCL 8 的表达通过抑制转录阻遏物 BLIMP 1 来抑制宿主防御
  • DOI:
  • 发表时间:
    2014
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Martina Severa;Sabina A. Islam;Stephen N. Waggoner;Zhaozhao Jiang;Nancy D. Kim;Glennice Ryan;Evelyn Kurt;Israel Charo;Daniel R. Caffrey;Victor L. Boyartchuk;Andy D. Luster;Katherine A. Fitzgerald
  • 通讯作者:
    Katherine A. Fitzgerald

Stephen N. Waggoner的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Stephen N. Waggoner', 18)}}的其他基金

Genetics of organ-specific lupus disease sequelae
器官特异性狼疮疾病后遗症的遗传学
  • 批准号:
    10221501
  • 财政年份:
    2020
  • 资助金额:
    $ 65.57万
  • 项目类别:
Genetics of organ-specific lupus disease sequelae
器官特异性狼疮疾病后遗症的遗传学
  • 批准号:
    10007204
  • 财政年份:
    2020
  • 资助金额:
    $ 65.57万
  • 项目类别:
Targeting natural killer cells to enhance HIV vaccine responses
针对自然杀伤细胞增强艾滋病毒疫苗反应
  • 批准号:
    10217993
  • 财政年份:
    2019
  • 资助金额:
    $ 65.57万
  • 项目类别:
Targeting natural killer cells to enhance HIV vaccine responses
针对自然杀伤细胞增强艾滋病毒疫苗反应
  • 批准号:
    10656405
  • 财政年份:
    2019
  • 资助金额:
    $ 65.57万
  • 项目类别:
A revolutionary vaccine approach to prevent HIV infection in substance abuse
一种革命性的疫苗方法,可预防药物滥用中的艾滋病毒感染
  • 批准号:
    8761595
  • 财政年份:
    2014
  • 资助金额:
    $ 65.57万
  • 项目类别:
A revolutionary vaccine approach to prevent HIV infection in substance abuse
一种革命性的疫苗方法,可预防药物滥用中的艾滋病毒感染
  • 批准号:
    8850414
  • 财政年份:
    2014
  • 资助金额:
    $ 65.57万
  • 项目类别:
A revolutionary vaccine approach to prevent HIV infection in substance abuse
一种革命性的疫苗方法,可预防药物滥用中的艾滋病毒感染
  • 批准号:
    9276657
  • 财政年份:
    2014
  • 资助金额:
    $ 65.57万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 65.57万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 65.57万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 65.57万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 65.57万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 65.57万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 65.57万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 65.57万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 65.57万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 65.57万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 65.57万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了